Animal Generic Drug User Fee Rates and Payment Procedures for Fiscal Year 2011, 45636-45640 [2010-19040]
Download as PDF
<![CDATA[
45636
Federal Register / Vol. 75, No. 148 / Tuesday, August 3, 2010 / Notices
erowe on DSK5CLS3C1PROD with NOTICES
Sheet can be mailed to: Food and Drug
Administration, P.O. Box 953877, St.
Louis, MO, 63195–3877.
If payment is made by wire transfer,
send payment to: U.S. Department of
Treasury, TREAS NYC, 33 Liberty St.,
New York, NY 10045, FDA Deposit
Account Number: 75060099, U.S.
Department of Treasury routing/transit
number: 021030004, SWIFT Number:
FRNYUS33. You are responsible for any
administrative costs associated with the
processing of a wire transfer. Contact
your bank or financial institution
regarding additional fees.
If you prefer to send a check by a
courier such as Federal Express
(FEDEX) or United Parcel Service (UPS),
the courier may deliver the check and
printed copy of the cover sheet to: U.S.
Bank, Attn: Government Lockbox
953877, 1005 Convention Plaza, St.
Louis, MO 63101. (Note: This address is
for courier delivery only. If you have
any questions concerning courier
delivery contact the U.S. Bank at 314–
418–4821. This telephone number is
only for questions about courier
delivery.)
The tax identification number of the
Food and Drug Administration is
530196965. (Note: In no case should the
payment for the fee be submitted to FDA
with the application.)
It is helpful if the fee arrives at the
bank at least a day or two before the
application arrives at FDA’s CVM. FDA
records the official application receipt
date as the later of the following: The
date the application was received by
FDA’s CVM, or the date U.S. Bank
notifies FDA that your payment in the
full amount has been received, or when
the U.S. Treasury notifies FDA of
receipt of an electronic or wire transfer
payment. U.S. Bank and the U.S.
Treasury are required to notify FDA
within 1 working day, using the PIN
described previously.
B. Application Cover Sheet Procedures
Step One—Create a user account and
password. Log on to the ADUFA Web
site at https://www.fda.gov/ForIndustry/
UserFees/AnimalDrugUserFee
ActADUFA/default.htm and, under
Tools and Resources click ‘‘The Animal
Drug User Fee Cover Sheet’’ and then
click ‘‘Create ADUFA User Fee Cover
Sheet.’’ For security reasons, each firm
submitting an application will be
assigned an organization identification
number, and each user will also be
required to set up a user account and
password the first time you use this site.
Online instructions will walk you
through this process.
Step Two—Create an Animal Drug
User Cover Sheet, transmit it to FDA,
VerDate Mar<15>2010
14:41 Aug 02, 2010
Jkt 220001
and print a copy. After logging into your
account with your user name and
password, complete the steps required
to create an Animal Drug User Fee
Cover Sheet. One cover sheet is needed
for each animal drug application or
supplement. Once you are satisfied that
the data on the cover sheet is accurate
and you have finalized the cover sheet,
you will be able to transmit it
electronically to FDA and you will be
able to print a copy of your cover sheet
showing your unique PIN.
Step Three—Send the payment for
your application as described in section
IX.A of this document.
Step Four—Please submit your
application and a copy of the completed
Animal Drug User Fee Cover Sheet to
the following address: Food and Drug
Administration, Center for Veterinary
Medicine, Document Control Unit
(HFV–199), 7500 Standish Pl.,
Rockville, MD 20855.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
drugs, on certain generic new animal
drug products, and on certain sponsors
of such abbreviated applications for
generic new animal drugs and/or
investigational submissions for generic
new animal drugs. This notice
establishes the fee rates for FY 2011.
For FY 2011, the generic animal drug
user fee rates are: $92,600 for each
abbreviated application for a generic
new animal drug; $5,440 for each
generic new animal drug product;
$55,950 for each generic new animal
drug sponsor paying 100 percent of the
sponsor fee; $41,963 for each generic
new animal drug sponsor paying 75
percent of the sponsor fee; and $27,975
for a generic new animal drug sponsor
paying 50 percent of the sponsor fee.
FDA will issue invoices for FY 2011
product and sponsor fees by December
31, 2010. These fees will be due and
payable within 30 days of the issuance
of the invoices.
The application fee rates are effective
for all abbreviated applications for a
generic new animal drug submitted on
or after October 1, 2010, and will remain
in effect through September 30, 2011.
Applications will not be accepted for
review until FDA has received full
payment of related application fees and
any other fees owed under the Animal
Generic Drug User Fee program.
FOR FURTHER INFORMATION CONTACT: Visit
the FDA Web site at https://www.fda.gov/
ForIndustry/UserFees/
AnimalGenericDrugUser
FeeActAGDUFA/default.htm or contact
Bryan Walsh, Center for Veterinary
Medicine (HFV–10), Food and Drug
Administration, 7529 Standish Pl.,
Rockville, MD 20855, 240–276–9730.
For general questions, you may also email the Center for Veterinary Medicine
(CVM) at: cvmagdufa@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
Food and Drug Administration
I. Background
[Docket No. FDA–2009–N–0340]
Section 741 of the act (21 U.S.C. 379j–
21) establishes three different kinds of
user fees: (1) Fees for certain types of
abbreviated applications for generic new
animal drugs, (2) annual fees for certain
generic new animal drug products, and
(3) annual fees for certain sponsors of
abbreviated applications for generic new
animal drugs and/or investigational
submissions for generic new animal
drugs (21 U.S.C. 379j–21(a)). When
certain conditions are met, FDA will
waive or reduce fees for generic new
animal drugs intended solely to provide
for a minor use or minor species
indication (21 U.S.C. 379j–21(d)).
For FY 2009 through FY 2013, the act
establishes aggregate yearly base
revenue amounts for each of these fee
C. Product, Establishment, and Sponsor
Fees
By December 31, 2010, FDA will issue
invoices and payment instructions for
product, establishment, and sponsor
fees for FY 2011 using this Fee
Schedule. Payment will be due and
payable within 30 days of issuance of
the invoice. FDA will issue invoices in
November 2011 for any products,
establishments, and sponsors subject to
fees for FY 2011 that qualify for fees
after the December 2010 billing.
Dated: July 29, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–19037 Filed 8–2–10; 8:45 am]
BILLING CODE 4160–01–S
Animal Generic Drug User Fee Rates
and Payment Procedures for Fiscal
Year 2011
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
rates and payment procedures for fiscal
year (FY) 2011 generic new animal drug
user fees. The Federal Food, Drug, and
Cosmetic Act (the act), as amended by
the Animal Generic Drug User Fee Act
of 2008 (AGDUFA), authorizes FDA to
collect user fees for certain abbreviated
applications for generic new animal
SUMMARY:
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
E:\FR\FM\03AUN1.SGM
03AUN1
45637
Federal Register / Vol. 75, No. 148 / Tuesday, August 3, 2010 / Notices
categories. Base revenue amounts
established for years after FY 2009 may
be adjusted for workload. Fees for
applications, products, and sponsors are
to be established each year by FDA so
that the revenue for each fee category
will approximate the level established
in the statute, after the level has been
adjusted for workload.
II. Revenue Amount for FY 2011
A. Statutory Fee Revenue Amounts
AGDUFA (Title II of Public Law 110–
316 signed by the President on August
14, 2008) specifies that the aggregate
revenue amount for FY 2011 for
abbreviated application fees is
$1,619,000 and each of the other two
generic new animal drug user fee
categories, annual product fees and
annual sponsor fees, is $1,889,000 each,
before any adjustment for workload is
made (see 21 U.S.C. 379j–21(b)).
B. Inflation Adjustment to Fee Revenue
Amount
The amounts established in AGDUFA
for each year for FY 2009 through FY
2013 include an inflation adjustment, so
no inflation adjustment is required.
C. Workload Adjustment to Inflation
Adjusted Fee Revenue Amount
For each FY beginning after FY 2009,
AGDUFA provides that statutory fee
revenue amounts shall be further
adjusted to reflect changes in review
workload (21 U.S.C. 379j–21(c)(1)).
FDA calculated the average number of
each of the four types of applications
and submissions specified in the
workload adjustment provision
(abbreviated applications for generic
new animal drugs, manufacturing
supplemental abbreviated applications
for generic new animal drugs,
investigational generic new animal drug
study submissions, and investigational
generic new animal drug protocol
submissions) received over the 5-year
period ended on September 30, 2008
(the base years), and the average number
of each of these types of applications
and submissions over the most recent 5year period that ended on June 30, 2010.
The results of these calculations are
presented in the first two columns of
table 1 of this document. Column 3
reflects the percent change in workload
over the two 5-year periods. Column 4
shows the weighting factor for each type
of application, reflecting how much of
the total FDA generic new animal drug
review workload was accounted for by
each type of application or submission
in the table during the most recent 5
years. Column 5 of table 1 is the
weighted percent change in each
category of workload, and was derived
by multiplying the weighting factor in
each line in column 4 by the percent
change from the base years in column 3.
At the bottom right of table 1, the sum
of the values in column 5 is calculated,
reflecting a total change in workload of
negative 24.47 percent for FY 2011. This
is the workload adjuster for FY 2011.
TABLE 1—WORKLOAD ADJUSTER CALCULATION
Application Type
Column 1
5-Year Avg. 2004–
2008 (Base Years)
Abbreviated New Animal Drug
Applications (ANADAs)
Column 2
Latest 5-Year Avg.
(thru June 30, 2010)
Column 3
Percent Change
Column 4
Weighting Factor
Colum 5
Weighted Percent
Change
44.2
30.2
-32%
56%
-17.74%
Manufacturing Supplements
ANADAs1
114.6
102.6
-10%
19%
-1.99%
Generic Investigational Study
Submissions2
17.4
17.4
0%
10%
0.00%
Generic Investigational Protocol
Submissions
21.6
15.2
-30%
16%
-4.74%
FY 2011 AGDUFA Workload Adjuster
-24.47%
1 This
erowe on DSK5CLS3C1PROD with NOTICES
number is slightly lower than the 114.8 shown in last year’s notice because FDA refused to file some applications.
2 This number is slightly lower than the 18 shown in last years notice because FDA refused to accept some submissions.
AGDUFA specifies that the workload
adjuster may not result in fees for a
fiscal year that are less than the
statutory revenue amount (21 U.S.C.
379j–21(c)(1)(B)) for that fiscal year.
Because applying the workload adjuster
for FY 2011 would result in fees less
than the statutory amount, the workload
adjustment will not be applied in FY
2011. As a result, the statutory revenue
amount for each category of fees for FY
2011 ($1,619,000 for application fees
and $1,889,000 for both product and
sponsor fees) becomes the revenue
target for the fees in FY 2011, for a total
fee revenue target in FY 2011 of
$5,397,000 for fees from all three
categories.
VerDate Mar<15>2010
14:41 Aug 02, 2010
Jkt 220001
III. Abbreviated Application Fee
Calculations for FY 2011
The term ‘‘abbreviated application for
a generic new animal drug’’ is defined
in 21 U.S.C. 379j–21(k)(1).
A. Application Fee Revenues and
Numbers of Fee-Paying Applications
The application fee must be paid for
abbreviated applications for a generic
new animal drug that is subject to fees
under AGDUFA and that is submitted
on or after July 1, 2008. The application
fees are to be set so that they will
generate $1,619,000 in fee revenue for
FY 2011. This is the amount set out in
the statute.
To set fees for abbreviated
applications for generic new animal
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
drugs to realize $1,619,000, FDA must
first make some assumptions about the
number of fee-paying abbreviated
applications it will receive during FY
2011.
The agency knows the number of
applications that have been submitted
in previous years. That number
fluctuates significantly from year to
year. FDA is making estimates and
applying different assumptions for two
types of submissions: Original
submissions of abbreviated applications
for generic new animal drugs and
‘‘reactivated’’ submissions of abbreviated
applications for generic new animal
drugs. Any original submissions of
abbreviated applications for generic new
animal drugs that were received by FDA
before July 1, 2008, were not assessed
E:\FR\FM\03AUN1.SGM
03AUN1
erowe on DSK5CLS3C1PROD with NOTICES
45638
Federal Register / Vol. 75, No. 148 / Tuesday, August 3, 2010 / Notices
fees (21 U.S.C. 379j–21(a)(1)(A)). Some
of these nonfee paying submissions
were later resubmitted after July 1
because the initial submission was not
approved by FDA (i.e. FDA marked the
submission as incomplete and requested
additional nonadministrative
information) or because the original
submission was withdrawn by the
sponsor. Because these abbreviated
applications for generic new animal
drugs are resubmitted after July 1, 2008,
they are assessed fees. In this notice,
FDA refers to these resubmitted
applications as ‘‘reactivated’’
applications.
Regarding original submissions of
abbreviated applications for generic new
animal drugs, FDA is assuming that the
number of applications that will pay
fees in FY 2011 will equal 30 percent
less than the average number of
submissions over the 5 most recent
years. This 30-percent reduction is
made because of the anticipated impact
of fees on the number on submissions.
During FY 2010, FDA estimates it will
receive only 6 original submissions of
abbreviated applications for generic new
animal drugs, compared to average
receipts of 14.4 per year over the latest
5 years, including our FY 2010 estimate.
Applying a 30-percent reduction to the
14.4 average, the estimate for original
submissions of abbreviated applications
for generic new animal drugs for FY
2011 is 10.1. (If the number of original
submissions of abbreviated applications
for generic new animal drugs does not
increase over the next year, a higher
percent reduction will have to be
applied a year from now when fees are
set for FY 2012.)
Regarding reactivated submissions of
abbreviated applications for generic new
animal drugs, FDA is applying a 50percent reduction based on the FDA’s
experience with these types of
submissions during the third year of
other user fee programs. This
assumption is based on the fact that
there were a limited number of original
submissions of abbreviated applications
for generic new animal drugs received
by FDA before July 1, 2008, and which
were not assessed fees. For these
original submissions that were not
approved before July 1, 2008,
resubmission to FDA would trigger an
application fee (21 U.S.C. 379j–
21(a)(1)(A)). Once these initial original
submissions of abbreviated applications
for generic new animal drugs received
by FDA before July 1, 2008, have either
been withdrawn or resubmitted,
‘‘reactivation submissions’’ will cease
completely. This reduction is consistent
with estimates made when this user fee
program was in the development
VerDate Mar<15>2010
14:41 Aug 02, 2010
Jkt 220001
process. During FY 2010, FDA estimates
it will receive only 9 reactivated
submissions of abbreviated applications
for generic new animal drugs, compared
to average receipts of 14.8 per year
average over the most recent 5 years,
including our estimate for FY 2010.
Applying a 50-percent reduction to the
14.8 average, the estimate for reactivated
submissions of abbreviated applications
for generic new animal drugs for FY
2011 is 7.4. These reductions may not
fully account for possible year to year
fluctuations in numbers of fee-paying
applications, but FDA believes that this
is a reasonable approach after about 7
years of experience with a similar user
fee program.
Based on the previous assumptions,
FDA is estimating that it will receive a
total of 17.5 fee paying generic new
animal drug applications in FY 2011
(10.1 original applications and 7.4
reactivations).
B. Fee Rates for FY 2011
FDA must set the fee rates for FY 2011
so that the estimated 17.5 abbreviated
applications that pay the fee will
generate a total of $1,619,000. To
generate this amount, the fee for a
generic new animal drug application,
rounded to the nearest hundred dollars,
will have to be $92,600.
IV. Generic New Animal Drug Product
Fee Calculations for FY 2011
A. Product Fee Revenues and Numbers
of Fee-Paying Products
The generic new animal drug product
fee (also referred to as the product fee)
must be paid annually by the person
named as the applicant in an
abbreviated new animal drug
application or supplemental abbreviated
application for generic new animal
drugs for an animal drug product
submitted for listing under section 510
of the act (21 U.S.C. 360), and who had
an abbreviated application for a generic
new animal drug or supplemental
abbreviated application for a generic
new animal drug pending at FDA after
September 1, 2008 (see 21 U.S.C. 379j–
21(a)(2)). The term ‘‘generic new animal
drug product’’ means each specific
strength or potency of a particular active
ingredient or ingredients in final dosage
form marketed by a particular
manufacturer or distributor, which is
uniquely identified by the labeler code
and product code portions of the
national drug code, and for which an
abbreviated application for a generic
new animal drug or supplemental
abbreviated application for a generic
new animal drug has been approved (21
U.S.C. 379j–21(k)(6)). The product fees
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
are to be set so that they will generate
$1,889,000 in fee revenue for FY 2011.
This is the amount set out in the statute
and no further adjustments are required
for FY 2011.
To set generic new animal drug
product fees to realize $1,889,000, FDA
must make some assumptions about the
number of products for which these fees
will be paid in FY 2011. FDA gathered
data on all generic new animal drug
products that have been submitted for
listing under section 510 of the act, and
matched this to the list of all persons
who FDA estimated would have an
abbreviated new animal drug
application or supplemental abbreviated
application pending after September 1,
2008. FDA estimates a total of 386
products submitted for listing by
persons who had an abbreviated
application for a generic new animal
drug or supplemental abbreviated
application for a generic new animal
drug pending after September 1, 2008.
Based on this, FDA believes that a total
of 386 products will be subject to this
fee in FY 2011. The number of products
has dropped substantially from the
numbers in last year’s Federal Register
fee notice because a number of products
were de-listed and are no longer subject
to fee. That also causes the fee per
product to increase.
In estimating the fee revenue to be
generated by generic new animal drug
product fees in FY 2011, FDA is
assuming that 10 percent of the
products invoiced, or 38.6, will not pay
fees in FY 2011 due to fee waivers and
reductions. Based on experience with
other user fee programs and the first 2
years of AGDUFA, FDA believes that
this is a reasonable basis for estimating
the number of fee-paying products in FY
2011.
Accordingly, the agency estimates
that a total of 347.4 (386 minus 38.6)
products will be subject to product fees
in FY 2011.
B. Product Fee Rates for FY 2011
FDA must set the fee rates for FY 2011
so that the estimated 347.4 products that
pay fees will generate a total of
$1,889,000. To generate this amount
will require the fee for a generic new
animal drug product, rounded to the
nearest five dollars, to be $5,440.
V. Generic New Animal Drug Sponsor
Fee Calculations for FY 2011
A. Sponsor Fee Revenues and Numbers
of Fee-Paying Sponsors
The generic new animal drug sponsor
fee (also referred to as the sponsor fee)
must be paid annually by each person
who: (1) Is named as the applicant in an
E:\FR\FM\03AUN1.SGM
03AUN1
Federal Register / Vol. 75, No. 148 / Tuesday, August 3, 2010 / Notices
abbreviated application for a new
generic animal drug, except for an
approved application for which all
subject products have been removed
from listing under section 510 of the act,
or has submitted an investigational
submission for a generic new animal
drug that has not been terminated or
otherwise rendered inactive; and (2) had
an abbreviated application for a generic
new animal drug, supplemental
abbreviated application for a generic
new animal drug, or investigational
submission for a generic new animal
drug pending at FDA after September 1,
2008 (see 21 U.S.C. 379j–21(k)(7) and
379j–21(a)(3)). A generic new animal
drug sponsor is subject to only one such
fee each fiscal year (see 21 U.S.C. 379j–
21(a)(3)(B)). Applicants with more than
6 approved abbreviated applications
will pay 100 percent of the sponsor fee,
applicants with 2 to 6 approved
abbreviated applications will pay 75
percent of the sponsor fee, and
applicants with 1 or fewer approved
abbreviated applications will pay 50
percent of the sponsor fee (see 21 U.S.C.
379j–21(a)(3)(B)). The sponsor fees are
to be set so that they will generate
$1,889,000 in fee revenue for FY 2011.
This is the amount set out in the statute
and no adjustments are required for FY
2011.
To set generic new animal drug
sponsor fees to realize $1,889,000, FDA
must make some assumptions about the
number of sponsors who will pay these
fees in FY 2011. Based on the number
of firms that meet this definition, FDA
estimates that in FY 2011, 12 sponsors
will pay 100 percent fees, 12 sponsors
will pay 75 percent fees, and 33
sponsors will pay 50 percent fees. That
totals the equivalent of 37.5 full sponsor
fees (12 times 100 percent or 12, plus 12
times 75 percent or 9, plus 33 times 50
percent or 16.5).
FDA estimates that about 10 percent
of all of these sponsors, or 3.75, may
qualify for a minor use/minor species
waiver.
Accordingly, the agency estimates
that the equivalent of 33.75 full sponsor
fees (37.5 minus 3.75) are likely to be
paid in FY 2011.
erowe on DSK5CLS3C1PROD with NOTICES
B. Sponsor Fee Rates for FY 2011
FDA must set the fee rates for FY 2011
so that the estimated equivalent of 33.75
full sponsor fees will generate a total of
$1,889,000. To generate this amount
will require the 100-percent fee for a
generic new animal drug sponsor,
rounded to the nearest $50, to be
$55,950. Accordingly, the fee for those
paying 75 percent of the full sponsor fee
will be $41,963, and the fee for those
VerDate Mar<15>2010
14:41 Aug 02, 2010
Jkt 220001
paying 50 percent of the full sponsor fee
will be $27,795.
VI. Fee Schedule for FY 2011
The fee rates for FY 2011 are
summarized in table 2 of this document.
TABLE 2—FY 2011 FEE RATES
Generic New Animal Drug
User Fee Category
Fee Rate for
FY 2011
Abbreviated Application Fee
for Generic New Animal
Drug Application
Generic New Animal Drug
Product Fee
$92,600
5,440
100 Percent Generic New
Animal Drug Sponsor Fee1
55,950
75 Percent Generic New Animal Drug Sponsor Fee 1
41,963
50 Percent Generic New Animal Drug Sponsor Fee 1
27,975
1 An
animal drug sponsor is subject to only
one fee each fiscal year.
VII. Procedures for Paying FY 2011
Generic New Animal Drug User Fees
A. Abbreviated Application Fees and
Payment Instructions
The FY 2011 fee established in the
new fee schedule must be paid for an
abbreviated new animal drug
application subject to fees under
AGDUFA that is submitted on or after
October 1, 2010. Payment must be made
in U.S. currency by check, bank draft, or
U.S. postal money order payable to the
order of the Food and Drug
Administration, by wire transfer, or by
automatic clearing house (ACH) using
Pay.gov. (The Pay.gov payment option is
available to you after you submit a cover
sheet. Click the ‘‘Pay Now’’ button). On
your check, bank draft, U.S. or postal
money order, please write your
application’s unique Payment
Identification Number, beginning with
the letters ‘‘AG’’, from the upper righthand corner of your completed Animal
Generic Drug User Fee Cover Sheet.
Also write the FDA post office box
number (PO Box 953877) on the
enclosed check, bank draft, or money
order. Your payment and a copy of the
completed Animal Generic Drug User
Fee Cover Sheet can be mailed to: Food
and Drug Administration, P.O. Box
953877, St. Louis, MO, 63195–3877.
If payment is made via wire transfer,
send payment to U.S. Department of the
Treasury, TREAS NYC, 33 Liberty St.,
New York, NY 10045, Account Name:
Food and Drug Administration, Account
Number: 75060099, Routing Number:
021030004, Swift Number: FRNYUS33.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
45639
You are responsible for any
administrative costs associated with the
processing of a wire transfer. Contact
your bank or financial institution
regarding the amount of the fees that
need to be paid in addition to the wire
transfer amount.
If you prefer to send a check by a
courier such as FEDEX or UPS, the
courier may deliver the check and
printed copy of the cover sheet to: US
Bank, Attn: Government Lockbox
953877, 1005 Convention Plaza, St.
Louis, Missouri 63101. (Note: This
address is for courier delivery only. If
you have any questions concerning
courier delivery contact the US Bank at
314–418–4821. This phone number is
only for questions about courier
delivery.)
The tax identification number of the
Food and Drug Administration is
530196965. (Note: In no case should the
payment for the fee be submitted to FDA
with the application.)
It is helpful if the fee arrives at the
bank at least a day or two before the
abbreviated application arrives at FDA’s
Center for Veterinary Medicine. FDA
records the official abbreviated
application receipt date as the later of
the following: The date the application
was received by FDA’s Center for
Veterinary Medicine, or the date US
Bank notifies FDA that your payment in
the full amount has been received, or
when the U.S. Department of the
Treasury notifies FDA of payment. US
Bank and the United States Treasury are
required to notify FDA within 1 working
day, using the Payment Identification
Number described previously.
B. Application Cover Sheet Procedures
Step One—Create a user account and
password. Log onto the AGDUFA Web
site at https://www.fda.gov/ForIndustry/
UserFees/AnimalGenericDrugUser
FeeActAGDUFA/ucm137049.htm and
scroll down the page until you find the
link ‘‘Create AGDUFA User Fee Cover
Sheet.’’ Click on that link and follow the
directions. For security reasons, each
firm submitting an application will be
assigned an organization identification
number, and each user will also be
required to set up a user account and
password the first time you use this site.
Online instructions will walk you
through this process.
Step Two—Create an Animal Generic
Drug User Fee Cover Sheet, transmit it
to FDA, and print a copy. After logging
into your account with your user name
and password, complete the steps
required to create an Animal Generic
Drug User Fee Cover Sheet. One cover
sheet is needed for each abbreviated
animal drug application. Once you are
E:\FR\FM\03AUN1.SGM
03AUN1
45640
Federal Register / Vol. 75, No. 148 / Tuesday, August 3, 2010 / Notices
satisfied that the data on the cover sheet
is accurate and you have finalized the
Cover Sheet, you will be able to transmit
it electronically to FDA and you will be
able to print a copy of your cover sheet
showing your unique Payment
Identification Number.
Step Three—Send the Payment for
your application as described in section
VII.A of this document.
Step Four—Please submit your
application and a copy of the completed
Animal Generic Drug User Fee Cover
Sheet to the following address: Food
and Drug Administration, Center for
Veterinary Medicine, Document Control
Unit (HFV–199), 7500 Standish Pl.,
Rockville, MD 20855.
C. Product and Sponsor Fees
By December 31, 2010, FDA will issue
invoices and payment instructions for
product and sponsor fees for FY 2011
using this fee schedule. Fees will be due
and payable 30 days after the issuance
of the invoices. FDA will issue invoices
in November 2012 for any products and
sponsors subject to fees for FY 2011 that
qualify for fees after the December 2010
billing.
Dated: July 29, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–19040 Filed 8–2–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–D–0246]
Draft Guidance for Industry on
Residual Drug in Transdermal and
Related Drug Delivery Systems;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance for
industry entitled ‘‘Residual Drug in
Transdermal and Related Drug Delivery
Systems.’’ This draft guidance provides
recommendations to developers and
manufacturers of transdermal drug
delivery systems (TDDS), transmucosal
drug delivery systems (TMDS), and
topical patch products regarding use of
an appropriate scientific approach
during product design and
development—as well as during
manufacturing and product lifecycle
management—to ensure that the amount
of residual drug substance at the end of
erowe on DSK5CLS3C1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
14:41 Aug 02, 2010
Jkt 220001
the labeled use period is minimized.
The draft guidance is applicable to
investigational new drug applications
(INDs), new drug applications (NDAs),
abbreviated new drug applications
(ANDAs), and supplemental new drug
applications (sNDAs) for TDDS, TMDS,
and topical patch products.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance, including
comments regarding the proposed
collection of information, by November
1, 2010.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201,
Silver Spring, MD 20993–0002. Send
one self-addressed adhesive label to
assist that office in processing your
requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance document.
Submit electronic comments on the
draft guidance to https://
www.regulations.gov. Submit written
comments on the draft guidance to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
FOR FURTHER INFORMATION CONTACT:
Terrance Ocheltree, Center for Drug
Evaluation and Research, Food and
Drug Administration, Bldg. 21, rm.
1609, 10903 New Hampshire Ave.,
Silver Spring, MD 20993–0002, 301–
796–1988.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
‘‘Residual Drug in Transdermal and
Related Drug Delivery Systems.’’ This
draft guidance provides
recommendations to developers and
manufacturers of TDDS, TMDS, and
topical patch products regarding use of
an appropriate scientific approach
during product design and
development—as well as during
manufacturing and product lifecycle
management—to ensure that the amount
of residual drug substance at the end of
the labeled use period is minimized.
Existing TDDS, TMDS, and topical
patches contain a larger amount of the
drug substance than what is intended to
be delivered to the patient. This excess
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
amount of drug substance is needed to
facilitate delivery of the intended
amount of the drug to the patient and
remains as residual drug in the used
system. The amount of residual drug
substance in TDDS, TMDS, and topical
patches has a significant potential to
impact the products’ quality, safety, and
efficacy. Consequently, it is necessary to
ensure that an appropriate scientific
approach is used to design and develop
these products. The approach should
ensure that the amount of residual drug
substance is minimized consistent with
the current state of technology.
Currently marketed TDDS, TMDS,
and topical patches may retain 10 to 95
percent of the initial total amount of
drug after the intended use period. This
raises a potential safety issue not only
to the patient, but also to others
including family members, caregivers,
children, and pets. For example, adverse
events due to a patient’s failure to
remove TDDS at the end of the intended
use period have been reported and are
generally related to an increased or
prolonged pharmacological effect of the
drug. Some children have died from
inadvertent exposure to discarded
TDDS. Reported adverse events
resulting from various quality problems
pertaining to TDDS have lead to product
recalls, withdrawals, and public health
advisories.
To reduce some of these risks, we
recommend that an enhanced design
and development approach—
specifically Quality by Design (QbD), as
described in the International
Conference on Harmonization (ICH)
guidance for industry Q8(R2)
Pharmaceutical Development—be used
when developing and manufacturing
TDDS, TMDS, and topical patches. We
also recommend that sufficient
scientific justification to support the
amount of residual drug in TDDS,
TMDS, or topical patches be included in
an application. The level of information
in the justification should be sufficient
to demonstrate product and process
understanding and ensure that a
scientific, risk-based approach has been
taken to minimize the amount of
residual drug in a system after use to the
lowest possible level. Furthermore, it is
expected that the amount of residual
drug in a newly developed system will
not exceed that of similar FDAapproved products.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the Agency’s current thinking
on residual drug in transdermal and
related drug delivery systems. It does
not create or confer any rights for or on
E:\FR\FM\03AUN1.SGM
03AUN1
]]>Agencies
[Federal Register Volume 75, Number 148 (Tuesday, August 3, 2010)]
[Notices]
[Pages 45636-45640]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-19040]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0340]
Animal Generic Drug User Fee Rates and Payment Procedures for
Fiscal Year 2011
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the rates
and payment procedures for fiscal year (FY) 2011 generic new animal
drug user fees. The Federal Food, Drug, and Cosmetic Act (the act), as
amended by the Animal Generic Drug User Fee Act of 2008 (AGDUFA),
authorizes FDA to collect user fees for certain abbreviated
applications for generic new animal drugs, on certain generic new
animal drug products, and on certain sponsors of such abbreviated
applications for generic new animal drugs and/or investigational
submissions for generic new animal drugs. This notice establishes the
fee rates for FY 2011.
For FY 2011, the generic animal drug user fee rates are: $92,600
for each abbreviated application for a generic new animal drug; $5,440
for each generic new animal drug product; $55,950 for each generic new
animal drug sponsor paying 100 percent of the sponsor fee; $41,963 for
each generic new animal drug sponsor paying 75 percent of the sponsor
fee; and $27,975 for a generic new animal drug sponsor paying 50
percent of the sponsor fee. FDA will issue invoices for FY 2011 product
and sponsor fees by December 31, 2010. These fees will be due and
payable within 30 days of the issuance of the invoices.
The application fee rates are effective for all abbreviated
applications for a generic new animal drug submitted on or after
October 1, 2010, and will remain in effect through September 30, 2011.
Applications will not be accepted for review until FDA has received
full payment of related application fees and any other fees owed under
the Animal Generic Drug User Fee program.
FOR FURTHER INFORMATION CONTACT: Visit the FDA Web site at https://www.fda.gov/ForIndustry/UserFees/AnimalGenericDrugUserFeeActAGDUFA/default.htm or contact Bryan Walsh, Center for Veterinary Medicine
(HFV-10), Food and Drug Administration, 7529 Standish Pl., Rockville,
MD 20855, 240-276-9730. For general questions, you may also e-mail the
Center for Veterinary Medicine (CVM) at: cvmagdufa@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Section 741 of the act (21 U.S.C. 379j-21) establishes three
different kinds of user fees: (1) Fees for certain types of abbreviated
applications for generic new animal drugs, (2) annual fees for certain
generic new animal drug products, and (3) annual fees for certain
sponsors of abbreviated applications for generic new animal drugs and/
or investigational submissions for generic new animal drugs (21 U.S.C.
379j-21(a)). When certain conditions are met, FDA will waive or reduce
fees for generic new animal drugs intended solely to provide for a
minor use or minor species indication (21 U.S.C. 379j-21(d)).
For FY 2009 through FY 2013, the act establishes aggregate yearly
base revenue amounts for each of these fee
[[Page 45637]]
categories. Base revenue amounts established for years after FY 2009
may be adjusted for workload. Fees for applications, products, and
sponsors are to be established each year by FDA so that the revenue for
each fee category will approximate the level established in the
statute, after the level has been adjusted for workload.
II. Revenue Amount for FY 2011
A. Statutory Fee Revenue Amounts
AGDUFA (Title II of Public Law 110-316 signed by the President on
August 14, 2008) specifies that the aggregate revenue amount for FY
2011 for abbreviated application fees is $1,619,000 and each of the
other two generic new animal drug user fee categories, annual product
fees and annual sponsor fees, is $1,889,000 each, before any adjustment
for workload is made (see 21 U.S.C. 379j-21(b)).
B. Inflation Adjustment to Fee Revenue Amount
The amounts established in AGDUFA for each year for FY 2009 through
FY 2013 include an inflation adjustment, so no inflation adjustment is
required.
C. Workload Adjustment to Inflation Adjusted Fee Revenue Amount
For each FY beginning after FY 2009, AGDUFA provides that statutory
fee revenue amounts shall be further adjusted to reflect changes in
review workload (21 U.S.C. 379j-21(c)(1)).
FDA calculated the average number of each of the four types of
applications and submissions specified in the workload adjustment
provision (abbreviated applications for generic new animal drugs,
manufacturing supplemental abbreviated applications for generic new
animal drugs, investigational generic new animal drug study
submissions, and investigational generic new animal drug protocol
submissions) received over the 5-year period ended on September 30,
2008 (the base years), and the average number of each of these types of
applications and submissions over the most recent 5-year period that
ended on June 30, 2010.
The results of these calculations are presented in the first two
columns of table 1 of this document. Column 3 reflects the percent
change in workload over the two 5-year periods. Column 4 shows the
weighting factor for each type of application, reflecting how much of
the total FDA generic new animal drug review workload was accounted for
by each type of application or submission in the table during the most
recent 5 years. Column 5 of table 1 is the weighted percent change in
each category of workload, and was derived by multiplying the weighting
factor in each line in column 4 by the percent change from the base
years in column 3. At the bottom right of table 1, the sum of the
values in column 5 is calculated, reflecting a total change in workload
of negative 24.47 percent for FY 2011. This is the workload adjuster
for FY 2011.
Table 1--Workload Adjuster Calculation
----------------------------------------------------------------------------------------------------------------
Column 1 5-Year Column 2 Latest 5-
Application Avg. 2004-2008 Year Avg. (thru June Column 3 Percent Column 4 Colum 5 Weighted
Type (Base Years) 30, 2010) Change Weighting Factor Percent Change
----------------------------------------------------------------------------------------------------------------
Abbreviated 44.2 30.2 -32% 56% -17.74%
New Animal
Drug
Application
s (ANADAs)
----------------------------------------------------------------------------------------------------------------
Manufacturin 114.6 102.6 -10% 19% -1.99%
g
Supplements
ANADAs\1\
----------------------------------------------------------------------------------------------------------------
Generic 17.4 17.4 0% 10% 0.00%
Investigati
onal Study
Submissions
\2\
----------------------------------------------------------------------------------------------------------------
Generic 21.6 15.2 -30% 16% -4.74%
Investigati
onal
Protocol
Submissions
----------------------------------------------------------------------------------------------------------------
FY 2011 AGDUFA Workload Adjuster -24.47%
----------------------------------------------------------------------------------------------------------------
\1\ This number is slightly lower than the 114.8 shown in last year's notice because FDA refused to file some
applications.
\2\ This number is slightly lower than the 18 shown in last years notice because FDA refused to accept some
submissions.
AGDUFA specifies that the workload adjuster may not result in fees
for a fiscal year that are less than the statutory revenue amount (21
U.S.C. 379j-21(c)(1)(B)) for that fiscal year. Because applying the
workload adjuster for FY 2011 would result in fees less than the
statutory amount, the workload adjustment will not be applied in FY
2011. As a result, the statutory revenue amount for each category of
fees for FY 2011 ($1,619,000 for application fees and $1,889,000 for
both product and sponsor fees) becomes the revenue target for the fees
in FY 2011, for a total fee revenue target in FY 2011 of $5,397,000 for
fees from all three categories.
III. Abbreviated Application Fee Calculations for FY 2011
The term ``abbreviated application for a generic new animal drug''
is defined in 21 U.S.C. 379j-21(k)(1).
A. Application Fee Revenues and Numbers of Fee-Paying Applications
The application fee must be paid for abbreviated applications for a
generic new animal drug that is subject to fees under AGDUFA and that
is submitted on or after July 1, 2008. The application fees are to be
set so that they will generate $1,619,000 in fee revenue for FY 2011.
This is the amount set out in the statute.
To set fees for abbreviated applications for generic new animal
drugs to realize $1,619,000, FDA must first make some assumptions about
the number of fee-paying abbreviated applications it will receive
during FY 2011.
The agency knows the number of applications that have been
submitted in previous years. That number fluctuates significantly from
year to year. FDA is making estimates and applying different
assumptions for two types of submissions: Original submissions of
abbreviated applications for generic new animal drugs and
``reactivated'' submissions of abbreviated applications for generic new
animal drugs. Any original submissions of abbreviated applications for
generic new animal drugs that were received by FDA before July 1, 2008,
were not assessed
[[Page 45638]]
fees (21 U.S.C. 379j-21(a)(1)(A)). Some of these nonfee paying
submissions were later resubmitted after July 1 because the initial
submission was not approved by FDA (i.e. FDA marked the submission as
incomplete and requested additional nonadministrative information) or
because the original submission was withdrawn by the sponsor. Because
these abbreviated applications for generic new animal drugs are
resubmitted after July 1, 2008, they are assessed fees. In this notice,
FDA refers to these resubmitted applications as ``reactivated''
applications.
Regarding original submissions of abbreviated applications for
generic new animal drugs, FDA is assuming that the number of
applications that will pay fees in FY 2011 will equal 30 percent less
than the average number of submissions over the 5 most recent years.
This 30-percent reduction is made because of the anticipated impact of
fees on the number on submissions. During FY 2010, FDA estimates it
will receive only 6 original submissions of abbreviated applications
for generic new animal drugs, compared to average receipts of 14.4 per
year over the latest 5 years, including our FY 2010 estimate. Applying
a 30-percent reduction to the 14.4 average, the estimate for original
submissions of abbreviated applications for generic new animal drugs
for FY 2011 is 10.1. (If the number of original submissions of
abbreviated applications for generic new animal drugs does not increase
over the next year, a higher percent reduction will have to be applied
a year from now when fees are set for FY 2012.)
Regarding reactivated submissions of abbreviated applications for
generic new animal drugs, FDA is applying a 50-percent reduction based
on the FDA's experience with these types of submissions during the
third year of other user fee programs. This assumption is based on the
fact that there were a limited number of original submissions of
abbreviated applications for generic new animal drugs received by FDA
before July 1, 2008, and which were not assessed fees. For these
original submissions that were not approved before July 1, 2008,
resubmission to FDA would trigger an application fee (21 U.S.C. 379j-
21(a)(1)(A)). Once these initial original submissions of abbreviated
applications for generic new animal drugs received by FDA before July
1, 2008, have either been withdrawn or resubmitted, ``reactivation
submissions'' will cease completely. This reduction is consistent with
estimates made when this user fee program was in the development
process. During FY 2010, FDA estimates it will receive only 9
reactivated submissions of abbreviated applications for generic new
animal drugs, compared to average receipts of 14.8 per year average
over the most recent 5 years, including our estimate for FY 2010.
Applying a 50-percent reduction to the 14.8 average, the estimate for
reactivated submissions of abbreviated applications for generic new
animal drugs for FY 2011 is 7.4. These reductions may not fully account
for possible year to year fluctuations in numbers of fee-paying
applications, but FDA believes that this is a reasonable approach after
about 7 years of experience with a similar user fee program.
Based on the previous assumptions, FDA is estimating that it will
receive a total of 17.5 fee paying generic new animal drug applications
in FY 2011 (10.1 original applications and 7.4 reactivations).
B. Fee Rates for FY 2011
FDA must set the fee rates for FY 2011 so that the estimated 17.5
abbreviated applications that pay the fee will generate a total of
$1,619,000. To generate this amount, the fee for a generic new animal
drug application, rounded to the nearest hundred dollars, will have to
be $92,600.
IV. Generic New Animal Drug Product Fee Calculations for FY 2011
A. Product Fee Revenues and Numbers of Fee-Paying Products
The generic new animal drug product fee (also referred to as the
product fee) must be paid annually by the person named as the applicant
in an abbreviated new animal drug application or supplemental
abbreviated application for generic new animal drugs for an animal drug
product submitted for listing under section 510 of the act (21 U.S.C.
360), and who had an abbreviated application for a generic new animal
drug or supplemental abbreviated application for a generic new animal
drug pending at FDA after September 1, 2008 (see 21 U.S.C. 379j-
21(a)(2)). The term ``generic new animal drug product'' means each
specific strength or potency of a particular active ingredient or
ingredients in final dosage form marketed by a particular manufacturer
or distributor, which is uniquely identified by the labeler code and
product code portions of the national drug code, and for which an
abbreviated application for a generic new animal drug or supplemental
abbreviated application for a generic new animal drug has been approved
(21 U.S.C. 379j-21(k)(6)). The product fees are to be set so that they
will generate $1,889,000 in fee revenue for FY 2011. This is the amount
set out in the statute and no further adjustments are required for FY
2011.
To set generic new animal drug product fees to realize $1,889,000,
FDA must make some assumptions about the number of products for which
these fees will be paid in FY 2011. FDA gathered data on all generic
new animal drug products that have been submitted for listing under
section 510 of the act, and matched this to the list of all persons who
FDA estimated would have an abbreviated new animal drug application or
supplemental abbreviated application pending after September 1, 2008.
FDA estimates a total of 386 products submitted for listing by persons
who had an abbreviated application for a generic new animal drug or
supplemental abbreviated application for a generic new animal drug
pending after September 1, 2008. Based on this, FDA believes that a
total of 386 products will be subject to this fee in FY 2011. The
number of products has dropped substantially from the numbers in last
year's Federal Register fee notice because a number of products were
de-listed and are no longer subject to fee. That also causes the fee
per product to increase.
In estimating the fee revenue to be generated by generic new animal
drug product fees in FY 2011, FDA is assuming that 10 percent of the
products invoiced, or 38.6, will not pay fees in FY 2011 due to fee
waivers and reductions. Based on experience with other user fee
programs and the first 2 years of AGDUFA, FDA believes that this is a
reasonable basis for estimating the number of fee-paying products in FY
2011.
Accordingly, the agency estimates that a total of 347.4 (386 minus
38.6) products will be subject to product fees in FY 2011.
B. Product Fee Rates for FY 2011
FDA must set the fee rates for FY 2011 so that the estimated 347.4
products that pay fees will generate a total of $1,889,000. To generate
this amount will require the fee for a generic new animal drug product,
rounded to the nearest five dollars, to be $5,440.
V. Generic New Animal Drug Sponsor Fee Calculations for FY 2011
A. Sponsor Fee Revenues and Numbers of Fee-Paying Sponsors
The generic new animal drug sponsor fee (also referred to as the
sponsor fee) must be paid annually by each person who: (1) Is named as
the applicant in an
[[Page 45639]]
abbreviated application for a new generic animal drug, except for an
approved application for which all subject products have been removed
from listing under section 510 of the act, or has submitted an
investigational submission for a generic new animal drug that has not
been terminated or otherwise rendered inactive; and (2) had an
abbreviated application for a generic new animal drug, supplemental
abbreviated application for a generic new animal drug, or
investigational submission for a generic new animal drug pending at FDA
after September 1, 2008 (see 21 U.S.C. 379j-21(k)(7) and 379j-
21(a)(3)). A generic new animal drug sponsor is subject to only one
such fee each fiscal year (see 21 U.S.C. 379j-21(a)(3)(B)). Applicants
with more than 6 approved abbreviated applications will pay 100 percent
of the sponsor fee, applicants with 2 to 6 approved abbreviated
applications will pay 75 percent of the sponsor fee, and applicants
with 1 or fewer approved abbreviated applications will pay 50 percent
of the sponsor fee (see 21 U.S.C. 379j-21(a)(3)(B)). The sponsor fees
are to be set so that they will generate $1,889,000 in fee revenue for
FY 2011. This is the amount set out in the statute and no adjustments
are required for FY 2011.
To set generic new animal drug sponsor fees to realize $1,889,000,
FDA must make some assumptions about the number of sponsors who will
pay these fees in FY 2011. Based on the number of firms that meet this
definition, FDA estimates that in FY 2011, 12 sponsors will pay 100
percent fees, 12 sponsors will pay 75 percent fees, and 33 sponsors
will pay 50 percent fees. That totals the equivalent of 37.5 full
sponsor fees (12 times 100 percent or 12, plus 12 times 75 percent or
9, plus 33 times 50 percent or 16.5).
FDA estimates that about 10 percent of all of these sponsors, or
3.75, may qualify for a minor use/minor species waiver.
Accordingly, the agency estimates that the equivalent of 33.75 full
sponsor fees (37.5 minus 3.75) are likely to be paid in FY 2011.
B. Sponsor Fee Rates for FY 2011
FDA must set the fee rates for FY 2011 so that the estimated
equivalent of 33.75 full sponsor fees will generate a total of
$1,889,000. To generate this amount will require the 100-percent fee
for a generic new animal drug sponsor, rounded to the nearest $50, to
be $55,950. Accordingly, the fee for those paying 75 percent of the
full sponsor fee will be $41,963, and the fee for those paying 50
percent of the full sponsor fee will be $27,795.
VI. Fee Schedule for FY 2011
The fee rates for FY 2011 are summarized in table 2 of this
document.
Table 2--FY 2011 Fee Rates
------------------------------------------------------------------------
Fee Rate for
Generic New Animal Drug User Fee Category FY 2011
------------------------------------------------------------------------
Abbreviated Application Fee for Generic New Animal Drug $92,600
Application
------------------------------------------------------------------------
Generic New Animal Drug Product Fee 5,440
------------------------------------------------------------------------
100 Percent Generic New Animal Drug Sponsor Fee\1\ 55,950
------------------------------------------------------------------------
75 Percent Generic New Animal Drug Sponsor Fee \1\ 41,963
------------------------------------------------------------------------
50 Percent Generic New Animal Drug Sponsor Fee \1\ 27,975
------------------------------------------------------------------------
\1\ An animal drug sponsor is subject to only one fee each fiscal year.
VII. Procedures for Paying FY 2011 Generic New Animal Drug User Fees
A. Abbreviated Application Fees and Payment Instructions
The FY 2011 fee established in the new fee schedule must be paid
for an abbreviated new animal drug application subject to fees under
AGDUFA that is submitted on or after October 1, 2010. Payment must be
made in U.S. currency by check, bank draft, or U.S. postal money order
payable to the order of the Food and Drug Administration, by wire
transfer, or by automatic clearing house (ACH) using Pay.gov. (The
Pay.gov payment option is available to you after you submit a cover
sheet. Click the ``Pay Now'' button). On your check, bank draft, U.S.
or postal money order, please write your application's unique Payment
Identification Number, beginning with the letters ``AG'', from the
upper right-hand corner of your completed Animal Generic Drug User Fee
Cover Sheet. Also write the FDA post office box number (PO Box 953877)
on the enclosed check, bank draft, or money order. Your payment and a
copy of the completed Animal Generic Drug User Fee Cover Sheet can be
mailed to: Food and Drug Administration, P.O. Box 953877, St. Louis,
MO, 63195-3877.
If payment is made via wire transfer, send payment to U.S.
Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY
10045, Account Name: Food and Drug Administration, Account Number:
75060099, Routing Number: 021030004, Swift Number: FRNYUS33. You are
responsible for any administrative costs associated with the processing
of a wire transfer. Contact your bank or financial institution
regarding the amount of the fees that need to be paid in addition to
the wire transfer amount.
If you prefer to send a check by a courier such as FEDEX or UPS,
the courier may deliver the check and printed copy of the cover sheet
to: US Bank, Attn: Government Lockbox 953877, 1005 Convention Plaza,
St. Louis, Missouri 63101. (Note: This address is for courier delivery
only. If you have any questions concerning courier delivery contact the
US Bank at 314-418-4821. This phone number is only for questions about
courier delivery.)
The tax identification number of the Food and Drug Administration
is 530196965. (Note: In no case should the payment for the fee be
submitted to FDA with the application.)
It is helpful if the fee arrives at the bank at least a day or two
before the abbreviated application arrives at FDA's Center for
Veterinary Medicine. FDA records the official abbreviated application
receipt date as the later of the following: The date the application
was received by FDA's Center for Veterinary Medicine, or the date US
Bank notifies FDA that your payment in the full amount has been
received, or when the U.S. Department of the Treasury notifies FDA of
payment. US Bank and the United States Treasury are required to notify
FDA within 1 working day, using the Payment Identification Number
described previously.
B. Application Cover Sheet Procedures
Step One--Create a user account and password. Log onto the AGDUFA
Web site at https://www.fda.gov/ForIndustry/UserFees/AnimalGenericDrugUserFeeActAGDUFA/ucm137049.htm and scroll down the
page until you find the link ``Create AGDUFA User Fee Cover Sheet.''
Click on that link and follow the directions. For security reasons,
each firm submitting an application will be assigned an organization
identification number, and each user will also be required to set up a
user account and password the first time you use this site. Online
instructions will walk you through this process.
Step Two--Create an Animal Generic Drug User Fee Cover Sheet,
transmit it to FDA, and print a copy. After logging into your account
with your user name and password, complete the steps required to create
an Animal Generic Drug User Fee Cover Sheet. One cover sheet is needed
for each abbreviated animal drug application. Once you are
[[Page 45640]]
satisfied that the data on the cover sheet is accurate and you have
finalized the Cover Sheet, you will be able to transmit it
electronically to FDA and you will be able to print a copy of your
cover sheet showing your unique Payment Identification Number.
Step Three--Send the Payment for your application as described in
section VII.A of this document.
Step Four--Please submit your application and a copy of the
completed Animal Generic Drug User Fee Cover Sheet to the following
address: Food and Drug Administration, Center for Veterinary Medicine,
Document Control Unit (HFV-199), 7500 Standish Pl., Rockville, MD
20855.
C. Product and Sponsor Fees
By December 31, 2010, FDA will issue invoices and payment
instructions for product and sponsor fees for FY 2011 using this fee
schedule. Fees will be due and payable 30 days after the issuance of
the invoices. FDA will issue invoices in November 2012 for any products
and sponsors subject to fees for FY 2011 that qualify for fees after
the December 2010 billing.
Dated: July 29, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-19040 Filed 8-2-10; 8:45 am]
BILLING CODE 4160-01-S
